Akums Drugs and Pharmaceuticals
From Wikipedia, the free encyclopedia
 Company Logo | |
| Akums | |
Company type | Public |
| NSE: AKUMS BSE: 544222 | |
| ISIN | INE09XN01023 |
| Industry | Pharmaceuticals, CDMO & Skincare |
| Founded | 2004 ; 21 years ago |
| Headquarters | Delhi, India |
Area served | Worldwide |
Key people | Sandeep Jain (Founder and Managing Director) Sanjeev Jain (Director) |
| Products | |
| Revenue |  ₹1,538.75 crore (US$180 million) (FY24) |
| Total assets | ₹2,095.43 crore (US$250 million) (FY24) |
Number of employees | 10,000+ (2024) |
| Subsidiaries |
|
| Website | www |
Akums Drugs and Pharmaceuticals Limited (Akums Group) is an Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO) that serves both domestic and multinational pharmaceutical companies.[1][2] The company was established in 2004 and became publicly listed on 6 August 2024.[3]
Akums was founded by Sanjeev Jain and Sandeep Jain in 2004, who currently serve as the managing directors of the company.[4] The company has 12 manufacturing facilities for various formulations and two facilities for producing active pharmaceutical ingredients (APIs).[5] It produces tablets, capsules, soft gels, dry syrups, liquid orals, and other pharmaceutical products.[6] Akums also operates four research and development (R&D) centers in India.[7] In 2020, the company received an investment of Rs 500 crore from Quadria Capital.[6]
In April 2022, the company acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited.[8] In May, the company received a license to manufacture and commercialize Bempedoic acid, a drug used to lower cholesterol. Two of the company's units in Haridwar were granted European GMP certification. One unit produces solid oral dosage forms, such as tablets and hard gelatin capsules, while the other manufactures large and small volume parenterals, including vials, ampoules, eye drops, and FFS formulations.[9] In August 2024, the company went public with a listing on the Bombay Stock Exchange and the National Stock Exchange.[3] In May 2025, Akums received a patent for an extended-release combination formulation of Doxylamine and Pyridoxine, indicated for the management of nausea and vomiting in pregnancy.[10]
In July and September 2025, Akums received Good manufacturing practice (GMP) certifications for its manufacturing facilities in Haridwar, including from Brazilian Health Regulatory Agency and the Eurasian Economic Union (EAEU) for its hormonal therapy unit.[11][12] In January 2026, two of its facilities in Haridwar, Uttarakhand, received European Union GMP certification issued by the Bulgarian Drug Agency (BDA).[13]
In November 2025, a 20-year patent for Dual Release Gastro-Resistant Composition effective from 19 November 2022, was granted to the company under the Patents Act, 1970.[14]
In February 2026, it received approval from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) to market rivaroxaban, an anticoagulant, in the country.[15]
Partnerships
In October 2024, Akums partnered with Microcore Research to use natural eggshell membrane (NESM) in the development of dietary supplements for joint and connective tissue health.[16]
In November 2023, Akums entered into a MoU with Delhi Pharmaceutical Sciences and Research University to collaborate on research and product development for patients in India.[17]
In October 2024, the company entered into a License and Distribution Agreement with Triple Hair Inc., a company based in New Brunswick, Canada. The agreement involved the licensing of a patented alopecia treatment from Triple Hair Group.[18]
In November 2024, Akums partnered with Caregen to introduce specialty nutraceuticals and cosmeceuticals in India.[19] During the same month, the company partnered with Jagdale to market ready-to-drink (RTD) nutritional beverages in India.[20]
In December 2024, Akums Drugs & Pharmaceuticals signed a long-term contract worth approximately ₹1,760 crore with a pharmaceutical company to manufacture and supply pharmaceutical formulations in the European market.[21][22]
In March 2025, the company signed a memorandum of understanding with National Institute of Food Technology Entrepreneurship and Management Thanjavur for collaboration on internships and research projects focused on nutraceutical product development and process improvement.[23] In April 2025, it signed a memorandum of agreement with Tamil Nadu Agricultural University for collaboration on research and development in pharmaceutical formulations.[24]
In August 2025, Akums and the Government of the Republic of Zambia announced a partnership to establish a pharmaceutical manufacturing facility in Zambia for the production of generic medicines, with construction of the facility subsequently initiated.[25][26]
In December 2025, Akums and Sharda University signed a memorandum of understanding to collaborate on pharmaceutical research, technology transfer, skill development, internships, and joint projects.[27]
Product development
In August 2023, Akums launched a formulation for managing Type-2 Diabetes in elderly patients,[28] which combines multiple medications to help control blood sugar levels.[29] On 15 September 2023, it introduced a fixed-dose combination capsule of Tamsulosin and Tadalafil, containing Tamsulosin 0.4 mg and Tadalafil 2.5 mg.[30] The company also began manufacturing nutraceutical gummies.[31][32]
In December 2023, Akums acquired a formulation facility in Baddi, Himachal Pradesh,[5] and announced the launch of Doxylamine and Pyridoxine extended-release tablets, which are approved by the Central Drugs Standard Control Organisation (CDSCO) in India and the United States Food and Drug Administration (US FDA).[33]
In 2024, the company launched several products, including Lasmiditan tablets,[34] nasal sprays,[35] Hydroxyurea for sickle cell anemia,[36] and a fixed-dose combination of Amlodipine, Telmisartan, and Metoprolol (extended-release) tablets for hypertension.[37][38]
In June 2024, Akums launched Rabeprazole + Levosulpiride SR Capsules as part of its new gastrointestinal formulations in India for the treatment of digestive health conditions.[39][40]
In January 2025, Akums has begun developing a new facility for lyophilized and sterile dosage manufacturing, focusing on injectables and biologics.[41] In February 2025, the company announced the launch of a combination therapy containing Dapagliflozin and Pioglitazone, indicated for the management of Type 2 Diabetes.[42] In April 2025, Akums announced the launch of a combination therapy containing Ripasudil and Timolol, indicated for the management of Glaucoma.[43]
In December 2025, Akums introduced an extended-release formulation of gabapentin for the management of postherpetic neuralgia (PHN), a chronic neuropathic pain condition associated with shingles.[44]